AQR Capital Management LLC Has $21.79 Million Holdings in Insulet Corporation $PODD

Key Points

• AQR Capital Management LLC has reduced its stake in Insulet Corporation by 16.5%, owning approximately 83,618 shares after selling 16,546 shares in Q1.
• Insulet reported $1.17 earnings per share for the latest quarter, exceeding analysts' expectations and showing a 32.9% increase in revenue compared to the same period last year.
• Multiple research firms have issued a 'buy' rating for Insulet, with price targets now ranging between $350.00 and $365.00, reflecting positive market sentiment.

AQR Capital Management LLC decreased its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 16.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,618 shares of the medical instruments supplier's stock after selling 16,546 shares during the period. AQR Capital Management LLC owned about 0.12% of Insulet worth $21,790,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PODD. Captrust Financial Advisors boosted its holdings in shares of Insulet by 24.1% during the fourth quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier's stock valued at $570,000 after acquiring an additional 425 shares during the period. Ethic Inc. boosted its holdings in shares of Insulet by 44.3% during the fourth quarter. Ethic Inc. now owns 5,462 shares of the medical instruments supplier's stock valued at $1,426,000 after acquiring an additional 1,678 shares during the period. Ellevest Inc. acquired a new position in shares of Insulet during the fourth quarter valued at $205,000. Gotham Asset Management LLC boosted its holdings in shares of Insulet by 57.2% during the fourth quarter. Gotham Asset Management LLC now owns 6,827 shares of the medical instruments supplier's stock valued at $1,782,000 after acquiring an additional 2,485 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Insulet by 7.0% during the fourth quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier's stock valued at $2,049,000 after acquiring an additional 511 shares during the period.

Insulet Price Performance

PODD stock traded up $3.84 during trading on Friday, hitting $341.78. The company had a trading volume of 472,873 shares, compared to its average volume of 530,837. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The business has a 50 day moving average of $311.59 and a 200 day moving average of $292.14. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The firm has a market capitalization of $24.06 billion, a price-to-earnings ratio of 103.88, a P/E/G ratio of 2.81 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same period in the previous year, the business earned $0.55 earnings per share. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PODD shares. The Goldman Sachs Group started coverage on shares of Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target for the company. Raymond James Financial reissued an "outperform" rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Wells Fargo & Company boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Barclays upped their price objective on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Royal Bank Of Canada upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Insulet has an average rating of "Moderate Buy" and an average price target of $335.12.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.